RTOG Protocol No. 8610 (Closed). "A phase III study of Zoladex and Flutamide used as cytoreductive agents in locally advanced carcinoma of the prostate treated with definitive radiotherapy." (Study chairmen: MV Pilepich, M Al-Sarraf, MJ John, DJ Grignon, DG McGowen; accrual 471 cases)

RTOG Protocol No. 90-20 (Closed). "A phase II trial of external beam radiation with Etanidazole (SR-2508) for the treatment of locally advanced prostate cancer." (Study Chairmen: CN Coleman, C Lawton, J Heaney, D Grignon, T Wasserman; accrual 38 cases)

RTOG Protocol No. 91-17 (Closed). "An observational clinical study of the significance of positive prostatic biopsies following full dose external beam irradiation of patients with bulky locally advanced adenocarcinoma of the prostate, stages T2b and T3, NX or N0 or N1, M0, previously treated on RTOG 86-10. (Study chairmen: MD Hafermann, RH Bard, DJ Grignon, E Hammond)

RTOG Protocol No. 92-02 (Closed). "A phase III trial of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate." (Study chairmen: GE Hanks, AT Porter, H Lepor, DJ Grignon; accrual 1554 cases)

RTOG Protocol No. 94-08 (Open). "A phase III trial of the study of endocrine therapy as a cytoreductive and cytostatic agent prior to radiation therapy in good prognosis locally confined adenocarcinoma of the prostate." (Study chairmen: DG McGowen, CU Jones, M Chetner, DJ Grignon; planned accrual 510 cases)

RTOG Protocol 96-01 (Open). "A phase III trial of radiation therapy with or without Casodex in patients with PSA elevation following radical prostatectomy for pT3NO carcinoma of the prostate." (Study chairmen: WU Shipley, D Raghavan, NM Heney and DJ Grignon; planned accrual 1220 patients).

RTOG Protocol 96-08 (Closed). "A phase III trial of total androgen suppression versus total androgen suppression plus definitive external beam radiation therapy for pathologic lymph node positive (pN+) adenocarcinoma of the prostate." (Study chairmen: CA Lawton, B. Donnelly and DJ Grignon, planned accrual 750 patients).

RTOG protocol 98-05 (Open). “Phase II Trial of transrectal ultrasound guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate.” (Study Chairmen CA Lawton, M Gillin, LG Gomella and DJ Grignon, planned accrual 95 patients).

RTOG protocol 99-02 (Open). “A phase III protocol of androgen suppression and radiation therapy vs. AS and RT followed by chemotherapy with poclitaxel estramustine and etoposide for localized, high risk prostate cancer.” (Study chairs: H Sandler, S Posenthal, K Pienta, L Gomella and D Grignon, planned accrual 1,440 patients).

RTOG protocol P-0011-1 (Open). “Phase III randomized study of adjuvant therapy for high-risk pT2-T3NO prostate cancer.” (Study chairs: R. Valicenti, K. Pienta, L. Gomella, D. Grignon and R. Choo; planned accrual 1398 patients).

Invited member, special review committee, Specialized Programs of Research Excellence (SPORE), Prostate Cancer, National Institute of Health, Bethesda, MD (1995)

Ad-hoc reviewer, National Cancer Institute, Bethesda, MD (1992 - present)

Reviewer, Abstracts (Genitourinary), United States - Canadian Academy of Pathology. (1992-1995; 2002-2004)

Invited reviewer: Cancer, Diagnostic Cytopathology, The Prostate, American Journal of Clinical Pathology, International Journal of Radiation Oncology Biology Physics, American Journal of Surgical Pathology, Urology, Journal of Urology, Journal of the National Cancer Institute

Reference Pathologist, "A phase III study of the use of cyproterone acetate as a cytoreductive agent in locally advanced carcinoma of the prostate treated with definitive radiotherapy." Berlex Canada, Lachine, Quebec. (Dr. A. Porter, Study Chairman; Closed accrual 208 cases)

Participant, Special Study Group for review of Specialized Programs of Research Excellence (SPORE) in Prostate Cancer, National Institutes of Health, Bethesda, MD, 1992

Member of Council, Ontario Medical Association Section on Laboratory Medicine, Toronto, Canada. (1989-1992)

Member, Genitourinary Pathology Panel, Canadian Reference Centre for Cancer Pathology, Ottawa, Canada (1988-1992)

Editorial Board Memberships

1. Journal of Genitourinary Pathology (1990-1992, Journal discontinued)

2. Journal of Urologic Pathology (1992-present)

The University of Western Ontario

June 1992 - July 1992 Clinical Associate Professor, Department of Pathology,

The University of Western Ontario

August 1992 - July 1997 Associate Professor of Pathology, Department of Pathology, Wayne State University

Administrative Experience

Director of Anatomical Pathology, Harper Hospital (1996-1999)

Member, Surgery Committee, Harper Hospital (1996-1999)

Member, Harper Hospital Q.A. Committee (1996-1999)

Developed and implemented Pathologist Workload Model (1997-present)

Member, Dermatology Chair Search Committee (1998-1999)

Interim Chairman, Department of Pathology (1999-2000)

Medical Director, DMC University Laboratories (1999-present)

Chief of Pathology, Harper Hospital (1999-present)

President, University Pathologists, P.C. (1999-present)

Member, Medical Staff Operating Committee, Harper Hospital (1999-present)

Member, Medical Executive Committee, Detroit Medical Center (1999-present)

Board Member, University Physicians Group (2000-present)

Member, Executive Committee, University Physicians Groups (2000-2001)

Member, Medical Leadership Executive Committee, Karmanos Cancer Institute (2000-2002)

Member, Medical Staff Operating Committee, Karmanos Cancer Hospital (2000-present)

Board Member, University Physicians Services Inc. (2000-present)

Board Member, Fund for Medical Research and Education, Wayne State University School of Medicine (2000-present)

Member, Internal Review Committee, Dept. of Biochemistry (2001)

Chairman, Urology Chair Search Committee (2001-2003)

President, University Pathology Research Services (2002-present)

Vice-Chair, Council of Clinical Chairs, Wayne State University (2002-2003)

Chair, Council of Clinical Chairs, Wayne State University (2004-2005)

Postgraduate Training Record

Dates

July 1987 – October 1988

January 1987 - June 1987

July 1982 – June 1986

June 1981 – June 1982

Institution

The University of Texas MD Anderson Cancer Center, Houston, Texas

The University of Western Ontario

St. Joseph's Hospital, London, Ontario

Position

Chief Fellow in Surgical Pathology

Fellow in Surgical Path-ology

Resident in Anatomic Path-ology

Rotating Intern

Academic Record

Dates

September 1977 -

June 1981

September 1974 -

June 1977

September 1969 -

June 1974

Institution

The University of Western Ontario, London, Ontario

Haileybury High School, Haileybury, Ontario

Degree

M.D.

B.Sc.

(Dean's Honor List)

Secondary School Diploma

Professional Associations

United States-Canadian Academy of Pathology

160. Cher ML, Lewis PE, Banerjee M, Sakr WA, Grignon DJ and Powell IJ. A similar pattern of chromosomal alterations in prostate cancers from African Americans and Caucasian Americans Clinical Cancer Res 4:1273-1278, 1998.

161. Louvar E, Littrup PJ, Goldstein A, Yu L, Sakr W and Grignon D. Correlation of color doppler flow in the prostate with tissue microvascularity. Cancer 83:135-140, 1998.

162. Gheiler EL, Tefilli MV, Tiguert R, Grignon D, Cher M, Sakr W, Pontes JE and Wood DP Jr. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 51:789-795, 1998.

163. Tefilli MV, Gheiler EL, Shekarriz B, Gomez de Oliveira J, Tiguert R, Grignon DJ and Pontes JE. Primary adenocarcinoma of the urethra with metastases to the glans penis: Successful treatment with chemothrapy and radiation therapy. Urology 52:517-519, 1998.

164. Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Sakr WA, Grignon DJ, Pontes JE and Wood DP Jr. Prognostic indicators in patients with seminal vesicle involvement following radical retropubic prostatectomy. J Urol 160:802-806, 1998.

165. Triest JA, Grignon DJ, Cher ML, Kocheril S, Montecillo EJ, Talati B, Tekyi-Mensah S, Pontes JE and Hillman GG. Systemic interleukin-2 therapy for human prostate tumors in a nude mouse model. Clin Cancer Res 4:2009-2014, 1998.

166. Jiminez RE, Raval MFT, Spanta R, Sakr W, Grignon DJ. Mesonephric remnants hyperplasia: A possible pitfall in the diagnosis of prostatic adenocarcinoma J Urologic Pathol 9:83-92, 1998.

167. Rakozy C, Grignon DJ, Sarkar FH, Sakr W, Littrup P, Forman J. Expression of bcl-2, p53 and p21 in benign and malignant prostate tissue before and after radiation therapy. Modern Pathol 11:892-899, 1998.

168. Nie D, Hillman GG, Geddes T, Tang K, Pierson C, Grignon DJ, Honn KV. Expression of platelet type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth in vivo. Cancer Res 58:4047-4051, 1998.

169. Cher ML, Bianco FJ Jr, Lam J, Davis LP, Grignon DJ, Sakr WA, Banerjee M, Pontes JE, Wood DP Jr. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160:1387-1391, 1998.

170. Adsay V, Sakr W, Grignon DJ, Crissman J, Sarkar F. Distribution of WAF1 (p21^WAF1) in normal and neoplastic prostate tissue. J Urologic Pathol 9:115-128, 1998.

171. Rakozy C, Grignon DJ, Sakr W, Forman J. Comparison of histologic changes in post-radiation therapy biopsies of patients treated with combined neutron and photon radiation therapy with or without neoadjuvant hormone ablation. Molecular Urology 2:91-93, 1998.

172. Sakr WA, Grignon DJ. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: Relationship to pathologic parameters, volume and spatial distribution of carcinoma of the prostate. Anal Quant Cytol Histol 20:417-423, 1998.

173. Trikha M, Cai Y, Grignon D, Honn KV. Identification of a novel truncated "IIb integrin. Cancer Res 58:4771-4775, 1998.

174. Tiguert R, Gheiler EL, Tefilli MV, Banerjee M, Sakr WA, Grignon DJ, Wood DP Jr., Powell IJ, Pontes JE. Racial differences and prognostic significance of tumor location in radical prostatectomy specimens. Prostate 37:230-235, 1998.

175. Sakr WA, Grignon DJ, Haas GP. Pathology of premalignant lesions and carcinoma of the prostate in African-American men. Semin Urol Oncol 16:214-220, 1998.

176. Bianco FJ Jr, Gervasi DC, Tiguert R, Grignon DJ, Pontes JE, Crissman JD, Fridman R, Wood DP Jr. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathologic stage and grade. Clinical Cancer Res 4:3011-3016, 1998.

177. Mohamed AN, Koppitch FC, El-Naggar M, Bakdounes KM, Grignon DJ. Chromosome analysis of six chromophobe renal cell carcinomas. J Urologic Pathol 9:223-231, 1998.

178. Tiguert R, Ravery V, Gheiler EL, Grignon DJ, Gudziak MR, Wood DP Jr., Pontes JE. Les cancers primitifs a petites cellules de las vessie. Progres en Urologie 1:1-5, 1999.

179. Tiguert R, Gheiler EL, Tefilli MV, Oskanian P, Banerjee M, Grignon DJ, Sakr WA, Pontes JE, Wood DP Jr. Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology 53:367-371, 1999.

180. Tefilli MV, Gheiler EL, Tiguert R, Sakr W, Grignon DJ, Banerjee M, Pontes JE, Wood DP Jr. Should Gleason score 7 prostate cancer be considered as a unique grade category? Urology 53:372-377, 1999.

181. Roach M III, Lu J, Pilepich MV, Asbell SO, Mohuidden M, Terry R, Grignon DJ. Long term survival after radiotherapy alone: Radiation Therapy Oncology Group prostate cancer trials. J Urol 161:864-868, 1999.

193. Sakr WA, Grignon DJ. Prostate. Practice parameters, pathologic staging, and handling radical prostatectomy specimens. Urol Clin North Am 26:453-63, 1999.

194. Grignon DJ, Bostwick DG, Civantos F, Garnick MB, Gaudin P, Srigley JR. Pathologic handling and reporting of prostate tissue specimens in patients receiving neoadjuvant hormonal therapy: Report of the pathology committee. Mol Urol 3:193-200, 1999.

195. Shekarriz B, Upadhyay J, Wood DP Jr, Hinman J, Raasch J, Cummings GD, Grignon DJ and Littrup PJ. Vesicourethral anastomosis biopsy after radical prostatectomy: Predictive value of prostate specific antigen and pathologic stage. Urology 54:1044-1048, 1999.

196. Nie D, Hillman GG, Geddes T, Tang K, Pierson C, Grignon DJ and Honn KV. Platelet-type 12-lipoxygenase regulates angiogenesis in human prostate carcinoma. Adv Exp Med Biol 469:623- 630, 1999.

197. Upadhyay J, Shekarriz B, Nemeth JA, Dong Z, Cummings GD, Fridman R, Sakr W, Grignon DJ, Cher ML. Membrane type 1 matrix metalloproteinase (MT1-MMP) immunolocalization in human prostate: Change in cellular localization associated with high grade prostatic intraepithelial neoplasia. Clin Cancer Res 5:4105-4110, 1999.

198. Kocheril S, Grignon DJ, Wang CY, Maughan RL, Montecillo EJ, Talati B, Tekyi-Mensah S, Pontes JE, Hillman GG. Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in mouse xenograft tumor model. Cancer Detection Prevention 23:408-416, 1999.

199. Powell IJ, Banerjee M, Novallo M, Sakr W, Grignon D, Wood DP, Pontes JE. Prostate cancer biochemical recurrence stage for stage is more frequent among African American versus Caucasian men with locally advanced but not organ confined disease. Urology 55:246-251, 2000.

200. Powell IJ, Banerjee M, Novallo M, Sakr W, Grignon D, Wood DP Jr., Pontes JE. Should the age specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years? J Urol 163:146-149, 2000.

201. Pierson C, Nassar H, Sakr W, Banerjee, RB, Grignon DJ. Primary malignant fibrous histiocytoma of the urinary bladder: A case report and review of the literature. J Urologic Pathol 11:195-205, 2000.

202. Tiguert R, Gheiler EL, Grignon DJ, Littrup PJ, Sakr W, Pontes JE, Wood DP. Patients with abnormal ultrasound of the prostate but normal digital examination should be classified as having clinical stage t2 tumors. J Urol 163:1486-90, 2000.

203. Roach M, Lu J, Pilepich MV, Asbell SO, Mohuidden M, Terry R, Grignon D. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47:609-15, 2000.

204. Roach M, Lu J, Pilepich MV, Asbell SO, Mohuidden M, Terry R, Grignon D, Lawton C, Shipley W, Cox J. Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 47:617-27, 2000.

205. Shekarriz B, Tiguert R, Upadhyay J, Gheiler E, Powell IJ, Pontes JE, Grignon DJ, Sakr W, Wood DP. Impact of location and multifocality of positive surgical margins on disease-free survival following radical prostatectomy: A comparison between African-American and white men. Urology 55:899-903, 2000.

206. Timar J, Raso E, Dome B, Li L, Grignon D, Nie D, Honn KV, Hagmann W. Expression,

subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. Int J Cancer 87:37-43, 2000.

207. Pierson C, Sakr W, Sarkar F, Pontes JE, Crissman JD, Grignon DJ. Retinoblastoma gene expression as a prognostic indicator in invasive bladder cancer. J Urologic Pathol 12:1-12, 2000.

208. Adsay V, Eble JN, Srigley JR, Jones EC and Grignon DJ. Mixed epithelial and stromal tumor of the kidney. Am J Surg Pathol 24:958-970, 2000.

209. Jimenez RE, Gheiler E, Oskanian P, Tiguert R, Sakr W, Wood Jr. DP, Pontes JE, Grignon DJ. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol 24:980-987, 2000.

210. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR, Yarborough J. Prognostic factors in prostate cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 124:995-1000, 2000.

211. Hammond ME, Fitzgibbons PL, Compton C, Grignon DJ, Page DL, Fielding LP, Bostwick D, Pajak T for Members of the Cancer Committee and Conference Participants. College of American Pathologists Conference XXXV: Solid tumor prognostic factors--which, how and so what? Summary document and recommendations for implementation. Arch Pathol Lab Med. 24:958-965, 2000.

212. Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 18:2740-6, 2000.

213. Jiminez RE, Tiguert R, An T, Grignon DJ, Lawrence D, Triest J. Unilateral hydronephrosis resulting from intraluminal obstruction of the ureter by adenosquamous endometrioid carcinoma arising from disseminated endometriosis. Urology 56:231, 2000.

214. Sakr WA, Ward C, Grignon DJ, Haas GP. Epidemiology and molecular biology of early prostatic neoplasia. Molecular Urol, 4:109-113, 2000.

215. Bentley G, Dey J, Sakr WA, Wood, Jr DP, Pontes JE, Grignon DJ. Significance of the Gleason scoring system after neoadjuvant hormonal therapy. Molecular Urol 4:125-129, 2000.

216. Sakr WA, Tefilli M, Grignon DJ, Banerjee M, Gheiler EL, Tiguert R, Powell IJ, Pontes EJ, Crissman JD, Wood DP Jr. Gleason score 7 prostate cancer: A heterogeneous entity. Correlation with pathologic parameters and disease free survival. Urology 56:730-734, 2000.

217. Hillman GG, Maughan RL, Grignon DJ, Yudelev M, Rubio J, Tekyi-Mensah S, Layer A , Che M, Forman JD. Neutron or photon irradiation for prostate tumors: Enhancement of cytokine therapy in a metastatic tumor model. Clinical Cancer Research 7:136-144, 2001.

218. Nie D, Zacharek A, Li L, Lamberti M, Tang Keqin, Hillman GG, Grignon D, Honn KV. Expression and function of thromboxane A₂ synthase in human prostate carcinoma. J Urol 165:474-477, 2001.

219. Jimenez RE, Eble JN, Reuter VE, Epstein JI, Folpe AL, de Peralta M, Tamboli P, Ansell ID, Grignon DJ, Young RH, Amin MB. Concurrent angiomyolipoma and renal cell neoplasia: A study of 36 cases. Mod Pathol 14:157-163, 2001.

220. Narain V, Tiguert R, Banerjee M, Grignon D, Wood DP, Powell IJ. Biochemical recurrence after radical prostatectomy in black and white American men with a positive or negative family history of prostate cancer. J Urol 165:474-477, 2001.

221. Pierson CR, Schober MS, Wallis T, Sarkar FH, Sorensen PHB, Eble JN, Srigley JR, Jones EC, Grignon DJ, Adsay V. Mixed epithelial and stromal tumor of the kidney lacks the genetic alterations of cellular congenital mesoblastic nephroma. Human Pathol 32:513-520, 2001.

222. Shekarriz B, Upadhyay J, Bianco FJ Jr, Tefilli MV, Tiguert R, Gheiler EL, Grignon DJ, Pontes JE, Wood DP Jr. Impact of sequential increase in preoperative serum PSA level up to 10 ng/ml on pathological findings and disease free survival. Prostate 48:136-143, 2001.

223. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243-1252, 2001.

224. Ku cuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik F, Li Y, Banerjee M, Grignon D, Bertram JS, Crissman JD, Pontes EJ, Wood Jr DP. Phase II randomized clinical trial of lycopene supplementation prior to radical prostatectomy. Cancer Epidemiol Biomarkers Prev 10:861-868, 2001.

225. Jimenez RE, Hussain M, Bianco FJ Jr, Vaishampayan U, Tabaczka P, Sakr WA, Pontes JE, Wood DP Jr, Grignon DJ. Her-2/neu Overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative anlaysis in primary and metastatic tumors. Clin Cancer Res 7:2440-2447, 2001.

226. Bianco FJ Jr, Sakr WA, Grignon DJ, Fridman R. Matrix-metalloproteinases and tissue inhibitors of metalloproteinases in bladder cancer. Urol Integr Invest 6:79-85, 2001.

227. Merati K, said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R, Philip P, Shields AF, Vaitkevicius V, Grignon DJ, Adsay, NV. Expression of inflammatory modulator cox-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol 24:447-52, 2001.

228. Tiguert R, Bianco J Jr, Oskanian P, Li Y, Grignon DJ, Wood DP Jr, Pontes JE, Sarkar FH. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. J Urol 166:2155-2160, 2001.

229. Narain V, Bianco FJ Jr, Grignon DJ, Sakr WA, Pontes JE, Wood DP Jr. How accurately does prostate biopsy Gleason score predict pathologic findings and disease free survival? Prostate 49:185-90, 2001.

230. Nie D, Che M, Grignon D, Tang K, Honn KV. Role of eicosanoids in prostate cancer progression. Cancer and Metastasis Reviews 20:195-206, 2001.

231. Powell IJ, Dey J, Dudley A, Pontes JE, Cher ML, Sakr W, Grignon DJ, Wood DP. Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: A multivariable analysis. J Urol 59:907-12, 2002.

232. Bianco FJ Jr, Wood DP Jr, Grignon DJ, Sakr WA, Pontes JE, Powell IJ. Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy. J Urol 168:479-482, 2002.

233. Tiguert R, Ravery V, Grignon DJ, Sakr W, Wood DP Jr, Pontes JE. [Significance of major grade of Gleason score 7 prostatic adenocarcinoma in progression after radical prostatectomy.] Prog Urol 12:31-36, 2002 [Article in French].

234. Pierson CR, McGowen R, Grignon D, Sakr W, Dey J, Sheng S. Maspin is up-regulated in premalignant prostate epithelia. Prostate 53:255-262, 2002.

235. Che M, Grignon D. Pathology of prostate cancer. Cancer and Metastasis Reviews 21:381-395, 2002.

236. Beach R, Gown AM, de Peralta-Venturina MN, Folpe AL, Yaziji H, Salles PG, Grignon DJ, Fanger GR, Amin MB. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 26:1588-1596, 2002.

237. Roach M III, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D. Race and survival of men treated for prostate cancer on Radiation Therapy Oncology Group phase III trials. J Urol 169:245-250, 2003.

238. Pollack A, Grignon DJ, Heydon KH, Hammond EH, Lawton CA, Mesic JB, Fu KK, Porter AT, Abrams RA, Shipley WU. Prostate cancer DNA ploidy response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: An analysis of RTOG 8610. J Clin Oncol 21:1238-48, 2003.

239. Che M, Sakr W, Grignon D. Pathologic features the urologist should expect on a prostate biopsy. Urologic Oncology: Seminars and Original Investigations 21:153-161, 2003.

240. Hillman GG, Maughan RL, Grignon DJ, Yudelev M, Che M, Abrams J, Wang Y, Layer A, Wright JL, Rubio J, Forman JD. Responsiveness of experimental prostate carcinoma bone tumors to neutron or photon radiation combined with cytokine therapy. Int J Radiat Oncol Biol Phys 56:1426-37, 2003.

241. Bianco FJ, Grignon DJ, Sakr WA, Shekarriz B, Upadhyay J, Dornelles E, Pontes JE. Radical prostatectomy with bladder neck preservation: Impact of a positive margin. Eur Urol 43:461-6, 2003.

242. Liao DJ, Du Q, Yu BW, Grignon D, Sarkar FH. Novel perspective: Focusing on the X chromosome in reproductive cancers. Cancer Investigation 21:641-658, 2003.

243. Pilepich MV, Winter K, Lawton C, Krisch RE, WolkovH, Movsas B, Hug E, Asbell S, Grignon D. Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate, long-term results of phase III RTOG study 85-31. Int J Radiat Oncol Biol Phys 57(2 Suppl):S172-3, 2003.

244. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21:3972-8, 2003.

245. Bismar TA, Bianco FJ, Zhang H, Li X, Sarkar FH, Sakr WA, Grignon DJ, Che M. Quantification of G250 mRNA expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin sections. J Pathol 35:513-517, 2003.

246. Nie D, Nemeth J, Qiao Y, Zacharek A, Li L, Hanna K, Tang K, Hillman GG, Cher ML, Grignon DJ, Honn KV. Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase. Clin Exp Metastasis 20:657-63, 2003.

247. Nie D, Che M, Zacharek A, Qiao Y, Li L, Lamberti M, Tang K, Cai Y, Guo Y, Grignon D, Honn KV. Differential expression of thromboxane synthase in prostate carcinoma: Role in tumor cell motility and perineural invasion. Am J Pathol 164:429-39, 2004.

248. Yang XJ, Sugimura J, Tretiakova MS, Furge K, Zagaja G, Sokoloff M, Pins M, Bergan R, Grignon DJ, Stadler WM, Vogelzang NJ, Teh BT. Gene expression profiling of renal medullary carcinoma: Potential clinical relevance. Cancer 100:976-85, 2004.

249. Grignon, D. Unusual subtypes of prostate cancer. Mod Pathol 17:316-27, 2004.

250. Bismar TA, Humphrey PA, Grignon DJ, Wang HL. Expression of b-Catenin in prostatic adenocarcinomas: A comparison with colorectal adenocarcinomas. Am J Clin Pathol 121:557-563, 2004.

251. Bianco FJ Jr, Justa D, Grignon DJ, Sakr WA, Pontes JE, Wood DP Jr. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 22:290-4, 2004.

252. Li R, Heydon K, Hammond ME, Grignon DJ, Roach M 3rd, Wolkov HB, Sandler HM, Shipley WU, Pollack A. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res 10:4118-24, 2004.

253. Nassar H, Pansare V, Zhang H, Che M, Sakr W, Ali-Fehmi R, Grignon D, Sarkar F, Cheng J, Adsay V. Pathogenesis of invasive micropapillary carcinoma: Role of MUC1 glycoprotein. Mod Pathol 17:1045-50, 2004.

254. McKenney JK, Amin MB, Srigley JR, Jimenez RE, Ro JY, Grignon DJ, Young RH. Basal cell proliferations of the prostate other than usual basal cell hyperplasia: A clinciopathologic study of 23 cases, including four carcinomas, with a proposed classification. Am J Surg Path 28:1289- 1298, 2004.

255. Lawton CA, Winters K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with D₁ (pN+) adenocarcinoma of the prostate (updated results based on a national prospective randomized trial, RTOG 85-31). (In press)

256. Altinok G, Kattar MM, Mohamed A, Poulik J, Grignon D, Rabah R. Translocations/TFE3 gene fusions and clinicopathological associations. Ped Develop Pathol. (In press)

257. Sakr WA, Grignon DJ, Powell IJ, Banerjee M, Littrup PJ, Wood DP Jr, Crissman JD, Pontes JE. Clinical and pathologic characteristics of stage T1c prostate cancer in African American and Caucasian patients treated by radical prostatectomy. (Submitted)

258. Sakr WA, Grignon DJ, Banerjee M, Powell IJ, Wood DP Jr, Pontes JE, Crissman JD. Predictors of biochemical recurrence in pathologically organ-confined prostate cancer: Analysis of PSA, age, race, Gleason score, tumor volume, HGPIN, DNA ploidy and proliferative activity. (Submitted)

259. Feng J, deGuia K, Ward C, Dey J, Grignon D, Powell I, Wood D, Pontes J, Sakr W. Changes in the frequency and volume of index tumors and high grade intraepithelial neoplasia in radical prostatectomy specimens in the 1990s. (Submitted)

260. Hillman GG, Maughan RL, Yudelev M, Che M, Grignon DJ, Wang Y, Layer A, Wright JL, Rubio J, Abrams J, Forman JD. Sequential administration of neutron and photon radiation for prostate carcinoma bone tumors in an experimental model. (Submitted)

261. Trikha M, Jin R, Cai Y, Grignon D, Honn KV. Identification of a truncated B3 integrin in solid tumors. (Submitted)

262. Altinok G, Powell I, Che M, Hormont K, Sarkar FH, Sakr W, Grignon D, Liao DJ. Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma. (Submitted)

Books

1. Banerjee D, Grignon DJ, and Frei JV (Eds.) Proceedings, DNA Flow Cytometry: Status and Controversies, London, Ontario; September 12 and 13, 1989. The University of Western Ontario, 1991.

2. Ro JY, Grignon DJ, Amin MB, Ayala AG. Atlas of Surgical Pathology of the Male Reproductive Tract. W.B. Saunders Co, Philadelphia, PA, 1996.

3. Amin MB, Grignon DJ, Humphrey P, Srigley JR. Gleason Grading: A Contemporary Approach. Lippincott, Williams and Wilkins, Philadelphia, PA, 2004.

4. Murphy WM, Grignon DJ, Perlman E. Tumors of the Kidney, Bladder, and Related Urinary Structures. Armed Forces Institute of Pathology, Atlas of Tumor Pathology, 4^th Series. AFIP Press, Washington, D.C., 2004.

Book Chapters

1. Grignon DJ. Bladder Neoplasms. In: Urologic Surgical Pathology. Eble JN and Bostwick D eds. Mosby Year Book, New York, NY, pp. 214-305, 1996.

2. True L and Grignon DJ. Pathology of Renal Cancers. In: Principles and Practice of Genitourinary Oncology, Raghaven D, Scher HI, Leibel SA and Lange P, eds. Lippincott Raven, Philadelphia, PA, pp. 799-811, 1996.

3. Haas GP, Grignon DJ and Montie J. Benign and Malignant Tumors of the Lower Urinary Tract. In: Diagnosis of Genitourinary Disease, 2nd Ed., Resnick MI and Older RA eds, Thieme Medical Publishers, New York, NY, 1997.

4. Porter AT, Littrup P, Grignon D, Forman J and Montie JE. Radiotherapy and Cryotherapy for Prostate Cancer. In: Campbell's Urology, 7th edition, Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ eds. W.B. Saunders Co., Philadelphia, PA, 1997.

5. Grignon DJ and Staerkel G. Surgical Diseases of the Kidney. In: Principles and Practice of Surgical and Cytopathology, 3rd edition. Silverberg SS, DeLellis R and Frable WJ eds. Churchill Livingstone Inc., New York, NY, 1997.

6. Grignon DJ and Eble JN. Renal Neoplasms. In: Heptinstall's Pathology of the Kidney 5th ed., Jennette JC, Olson JL, Schwartz MM and Silva FG, eds. Lippincott-Raven Publishers, Philadelphia, PA, 1998.

7. Sakr WA and Grignon DJ. Pathology and Molecular Biology of Early Prostate Cancer. In: Molecular Pathology of Early Cancer, Srivastava S, ed. IOS Press, 1999.

8. Grignon DJ and Sakr WA. Pathology of Prostate Cancer. In: Prostate Cancer. Honn KV and Wood DP Jr., eds., JAI Press Inc., Greenwich, Conn., 1999.

9. Grignon DJ. Pathologic Predictors of Treatment Outcome. In: Radiotherapy of Prostate Cancer. Greco C and Zelefsky M, eds. Harwood Academic Publishers, Amsterdam, 2000.

10. Grignon DJ. Pathology of Renal Cell Carcinoma. In: Renal Cancer: Methods and Protocols. Mydlo J, Editor. The Humana Press, Totowa, NJ, 2001.

11. Bentley G and Grignon DJ. Non Transitional Epithelial Tumors. In: Pathology of the Urinary Bladder. Foster CS and Ross J, Editors. W.B. Saunders Co, Orlando, FL, 2003 (in press).

12. Grignon DJ, Eble JN, Bonsib SM, Moch H. Tumors of the kidney: Clear cell renal cell carcinoma. In: WHO Classification of Tumours of the Urinary System and Male Genital Organs; Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. IARC Press, Lyon, 2004. pp 23-25

13. Eble JN, Grignon DJ, Moch H. Tumors of the kidney: Metanephric adenoma and metanephric adenofibroma. In: WHO Classification of Tumours of the Urinary System and Male Genital Organs; Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. IARC Press, Lyon, 2004. pp 44-46.

14. Sauter G, Algaba F, Amin MB, Busch C, Cheville J, Gasser T, Grignon DJ, Hofstadter F, Lopez-Beltran A, Epstein JI. Tumors of the urinary system: Non-invasive urothelial tumours. In: WHO Classification of Tumours of the Urinary System and Male Genital Organs; Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. IARC Press, Lyon, 2004. pp 110.

15. Grignon DJ, El-Bolkainy MN, Schmitz-Drager BJ, Simon R, Tyczynski JE. Tumors of the urinary system: Squamous cell carcinoma. In: WHO Classification of Tumours of the Urinary System and Male Genital Organs; Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. IARC Press, Lyon, 2004. pp 124-127.

16. Grignon DJ, El-Bolkainy MN. Tumors of the urinary system: Verrucous squamous cell carcinoma. In: WHO Classification of Tumours of the Urinary System and Male Genital Organs; Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. IARC Press, Lyon, 2004. pp 127.

17. Helpap B, Ayala AG, Grignon DJ, Oliva E, Epstein JI. Tumors of the urinary system: Metastatic tumours and secondary extension in urinary bladder. In: WHO Classification of Tumours of the Urinary System and Male Genital Organs; Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. IARC Press, Lyon, 2004. pp148-149.

18. Grignon DJ. Tumors of the prostate: Urothelial carcinoma. In: WHO Classification of Tumours of the Urinary System and Male Genital Organs; Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. IARC Press, Lyon, 2004. pp 202-204.

19. Grignon D. Non urothelial epithelial tumors. In: Textbook of Bladder Cancer; Lerner SP, Schoenberg M, Sternberg C, eds. T&F Informa, London, 2005 (in preparation).

20. Che M, Grignon DJ. Handling and reporting of tumor-containing kidney specimens. In: Clin Lab Med; Elsevier Saunders, Philadelphia, PA. (In press)

Other

1. Recommendations for the Reporting of Resected Prostate Carcinoma. Association of Directors of Anatomic and Surgical Pathology (ad hoc committee: Amin MB, Grignon D, Bostwick D, Reuter V, Troncoso P, Troncoso P, Ro JY, Ayala AG). Hum Pathol 27:321-323, 1996.

2. Consensus Statement: Guidelines for PSA Following Radiation Therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel (Cox JD, Grignon DJ, Kaplan RS, Parsons JT, Schellhammer PF). Int J Radiation Oncology Biol Phys 37:1035-1041, 1997.

3. Amin MB, Ro J, Ayala AG, Grignon DJ, Tamboli P. Atlas of Prostate Pathology 1.0 on CD-ROM. Chapman & Hall, March 1997.

4. Amin MB, Grignon DJ, Bostwick DG, Epstein JI, Reuter VE, Troncoso P, Ro JY, Ayala AG. Recommendations for reporting prostatic carcinomas with commentary. Pathol Case Rev 3:223-232,

1998.

5. Garnick MB, Fair WR, Goldenberg SL, Gleave M, Fourcroy J, Grignon D, Srougi M, Porterfield H, Hart C. Third International Conference on Neoadjuvant Hormonal Therapy of Prostate Cancer: Overview Consensus Statement. Molecular Urol 3:171-174, 1999.

6. Epstein JI, Amin MB, Reuter VR, Mostofi FK, and the WHO/ISUP Bladder Consensus Conference Committee. The World Health Organization (WHO) and International Society of Urological Pathologists (ISUP) consensus classification of urothelial (transitional cell) lesions. Am J Surg Pathol 22:1435-1448, 1999.

7. Grignon DJ. Pathologic and biologic markers for prostate adenocarcinoma. American Society of Clinical Oncologists Educational Book, ASCO, Alexandria, VA, 1999.

8. Srigley JR, Amin MB, Bostwick DG, Grignon DJ, Hammond ME. Updated protocol for the examination of specimens from patients with carcinoma of the prostate gland: A basis for checklists. Arch Pathol Lab Med 124:1034-1039, 2000.

9. Garnick MB, Fair WR, Bostwick D, Debruyne F, Fourcroy J, Grignon D, Porterfield H, Sufrin G, Thrasher B, Hart C. Fourth International Conference on Neoadjuvant Hormonal Therapy of Prostate Cancer: Overview Consensus Statement. Molecular Urol 4:89-92, 2000.

10. Grignon D, Amin M, Brat D, El-Nagaar A, Hammond E, Lucas D, Nelson J, Petito C, Scott C, Sheahan DG, Sneige N, True L, Yesner R. Pathology Committee. Int J Radiat Oncol Biol Phys 51:110-2, 2001.

11. Hammond ME, Ang K, Byhardt R, Campbell B, Chapman JD, Eisenberg B, Greven K, Harris J, Hoffman J, Lange C, McCormick B, Mehta M, Sandler H, Trotti A, Willet C, Wolfson A, Furness A, Jensen T, Grignon D, Okunieff P. Tumor Utilization Committee. Int J Radiat Oncol Biol Phys 51:103-9, 2001.

12. Okunieff P, Hammond E, Grignon D, et al. Translational Research Program. Int J Radiat Oncol Biol Phys 51:75-87, 2001.

13. Sandler H, Shipley WU, Gomella L, Pienta K, Bard RH, Bruner D, Clark R, DeSilvio M, Gaspar L, Gillin M, Grignon D, et al. Genitourinary Cancer Committee. Int J Radiat Oncol Biol Phys 51:28-38, 2001.

14. Amin MB, Srigley JR, Grignon DJ, Reuter VE, Humphrey PA, Cohen MB, Hammond ME. Updated protocol for the examination of specimens from patients with carcinoma of the urinary bladder, ureter, and renal pelvis. Cancer Committee, College of American Pathologists. Arch Pathol Lab Med 127:1263-79, 2003.

Abstracts (Last 3 years only)

234. Ward C, Angelakis K, deGuia K, Pansare V, Grignon D, Sakr WA. Fluorescence in situ hybridization amplification of HER2/neu in African-Americans (AA) and Caucasians treated by radical prostatectomy for clinically localized prostate cancer (PCA): Correlation with stage and biochemical recurrence. J Urol 165:141, 2001.

235. Bianco FJ, Wood DP, Pontes JE, Sakr WA, Grignon DJ, Powell IJ. Prostate cancer stage shift has eliminated the gap in survival between African American and Caucasian men after radical prostatectomy. J Urol 165:232, 2001.

236. Herzog ME, Nemeth JA, Yousif R, Reddy A, Hussain M, Grignon DJ, Honn KV, Che M, Cher ML. Histomorphometric, histologic, and radiologic comparison of clinical and experimental human prostate cancer bone metastases. J Urol 165:287, 2001.

237. Andea A, Dey J, deGuia K, Grignon DJ, Pontes JE, Wood DP, Powell IJ, Sakr WA. Modeling prostate cancer distribution for exceedingly small tumor volumes in radical prostatectomy specimens: Implications for biopsy approach. J Urol 165:310, 2001.

238. Bianco FJ, Wood DP, Grignon DJ, Sakr WA, Pontes JE, Powell IJ. Presence of extraprostatic disease after radical prostatectomy diminish survival significantly in African American men. J Urol 165:330, 2001.

239. Ali-Fehmi R, Merati K, Grignon D, Sakr W. Proliferative index and cell cycle regulators expression in high grade prostatic intraepithelial neoplasia (HGPIN) and ductal “endometroid” prostatic carcinoma (DPCA). Mod Pathol 14, 2001.

240. Bentley G, Raz A, Jimenez R, Sakr W, Tait L, Wood Jr D, Grignon D. Galectin-3, MMP-2 and MMP-9 expression in the invasive component of urothelial carcinoma of the bladder. Mod Pathol 14, 2001.

241. Butler C, Andea D, Pansare V, Dey J, Grignon D, Haas G and Sakr W. Latent “preclinical” carcinoma of the prostate (CAP) and high grade prostatic intraepithelial neoplasia (HGPIN): Different pathways for the development of clinically evident CAP? Mod Pathol 14, 2001.

242. Che M, Nemeth J, Sochaki P, Cher ML and Grignon D. Bone metastasis of prostate cancer: A histopathological and immunohistochemical study. Mod Pathol 14, 2001.

243. deGuia K, Andea A, Butler C, Feng J, Grignon D and Sakr W. Small volume prostate cancer (PCa) in patients 50 years or younger treated by radical prostatectomy is more multi focal and associated with a more diffuse high grade prostatic intraepithelial neoplasia (HGPIN). Mod Pathol 14, 2001.

244. Jimenez RE, Lu JD, Roach M, Pilepich MV, Sause W, Brassachio R, Lawton C, Grignon D. Mitotic figures as a prognostic marker in prostate cancer (PCa) patients treated with radiation therapy: A Radiation Therapy Oncology Group (RTOG) study. Mod Pathol 14, 2001.

245. McKenney JK, Amin MB, Srigley JR, Ro JY, Jimenez R, Grignon DJ, Young RH. Adenoid basal proliferations of the prostate other than usual basal cell hyperplasia: A study of 23 cases with a proposed classification. Mod Pathol 14, 2001.

246. Nassar H, Butler C, Pansare V, Sarkar F, Grignon D and Sakr W. Low and high grade prostatic intraepithelial neoplasia (PIN), a biologic spectrum?: Evaluation of cell cycle regulators and neovascularization. Mod Pathol 14, 2001.

247. Sakr WA, Srigley JR, Dey J, Amin MB, Bostwick DG, Epstein JI, Grignon DJ, Humphrey PA, Jones EC, Trancoso P, Wheeler TM, Young RH. What features do urologic pathologists emphasize in diagnosing intraepithelial neoplasia (PIN)? A study of morphologic criteria and reproducibility. Mod Pathol 14, 2001.

248. Ingber M, Bentley G, Grignon D, Tabaczka P, Majumar A, Sarkar F. Expression of a novel epidermal growth factor receptor-related protein in muscle invasive urothelial carcinoma. Mod Pathol 15:165A, 2002.

249. Srigley J, Kapusta L, Reuter V, Amin M, Grignon D, Eble J, Weber A, Moch H. Phenotypic, molecular and ultrastructural studies of a novel low grade renal epithelial neoplasm possibly related to the loop of Henle. Mod Pathol 15:182A, 2002.

250. Srigley J, Grignon DJ, Young RH. The distinction between pure carcinoid tumor and carcinoid-like adenocarcinoma of the prostate gland. Mod Pathol 15:182A, 2002.

251. Nie D, Zacharek A, Che M, Cai Y, Qiao Y, Lamberti M, Tang K, Grignon D, Honn KV. Expression, regulation and function of thromboxane A2 synthase in cancer. Proc AACR 43:1, 2002.

252. Pansare V, Butler C, Haas G, Grignon D, Sakr W. Progression model of subclinical prostate cancer (PCA): Observations of tumor volume, grade and multicentricity in an autopsy series of 1027 cases. Mod Pathol 16:6A, 2003.

253. Bismar TA, Zhang H, Li X, Sakr WA, Che M, Grignon DJ. G250 expression in multiple epithelial renal neoplasms, including multi-locular cystic renal cell carcinoma. Mod Pathol 16:143A, 2003.

254. Bismar TA, Che M, Sakr WA, Grignon DJ. The value of immunohistochemistry in the diagnosis of epithelial renal neoplasms with pink cytoplasm. Mod Pathol 16:142A, 2003.

255. Butler C, Andea A, Pansare V, Hong X, Sarkar F, Grignon D, Sakr W. Comparative molecular and morphologic analysis of autopsy discovered and clinically evident prostatic carcinoma: Loss of heterozygosity analysis. Mod Pathol 16:144A, 2003.

256. Sakr W, Grignon D, Srigley J, Troncoso P, Tamboli P, Lopez-Corona E, Reuter V. Recent trends regarding the significance of isolated high grade prostatic intraepithelial neoplasia “HGPIN” in predicting prostate cancer “PCA” on follow up biopsies: Is there a change in confirming cancer diagnosis? A multi institutional study. Mod Pathol 16:168A, 2003.

257. Sakr W, Che M, Kolizeras K, Grignon D. Clinicopathological characteristics of patients treated by radical prostatectomy (RP) following the diagnosis of prostate cancer (PCA) of a single, less than 1 mm focus in one core biopsy. Mod Pathol 16:168A, 2003.

258. Shen R, Zhang H, Li X, Bismar T, Bhan R, Vernick J, Madan S, Sarkar F, Sakr W, Grignon D, Che M. Applications of a reliable quantitative gene analysis approach in urological tumors. Mod Pathol 16:170A, 2003.

259. Shen R, Zhang H, Li X, Bismar T, Sakr W, Grignon D, Che M. Differential role of angiogenesis in clear cell and chromophobe renal cell carcinoma and oncocytoma. Mod Pathol 16:171A, 2003.

260. Zhang H, Li, X, Sarkar F, Sakr W, Grignon D, Che M. HIF and COX-2 are potential early modulators of tumor angiogenesis in human prostate cancer. Mod Pathol 16:177A, 2003.

261. Zhang H, Bianco F, Bismar T, Bentley G, Sakr W, Grignon D, Che M. Comparison of clinical outcomes of conventional high grade invasive urothelial carcinoma with urothelial carcinoma exhibiting aggressive histological features. Mod Pathol 16:177A, 2003.

262. Nassar H, Pansare V, Zhang H. Kotcher G, Che M, Sakr W, Ali-Fehmi R, Grignon D, Sarkar F, Cheng J, Adsay NV. Reverse polarization of cells with expression of MUC1 in the stroma-facing surfaces may be a key factor in the pathogenesis and morphogenesis of invasive micropapillary carcinoma. Mod Pathol 16:298A, 2003.

263. Pilepich M, Winter K, Lawton C, Krisch R, Wolkov H, Movsas B, Hug E, Asbell S, Grignon D. Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate. Long term results of Phase III RTOG Study 8531. RTOG Session J 11:30, #82, 2003.

264. Pansare V, Kolizeras K, Alousi S, Kotcher G, Butler C, Grignon D, Sakr W. Inflammation, atrophy and early neoplastic transformation of prostatic epithelium: Indication of a potential carcinogenic pathway? Mod Pathol 17:7A, 2004.

265. Adsay NV, Che M, Basturk O, Tamboli P, Sakr W, Amin M, Grignon DJ. Sarcomatous transformation in mixed epithelial stromal tumors of the kidney (malignant MEST). Mod Pathol 17:135A, 2004.

266. Altinok G, Che M, Bismar T, Bianco F, Sakr W, Pontes JE, Grignon D. Clincopathologic and immunohistochemical features distinguish type 1 from type 2 sporadic papillary renal cell carcinoma. Mod Pathol 17:136A, 2004.

267. Amin MB, MacLennan GT, Paraf F, Cheville JC, Vieillefond A, Radhakrishnan A, Che M, Srigley JR, Grignon DJ. Tubulocystic carcinoma of the kidney: Clincopathologic analysis of 29 cases of a distinctive rare subtype of renal cell carcinoma (RCC). Mod Pathol 17:137A, 2004.

268. Bentley G, Che M, Vaishampayan U, Sakr W, Grignon D. Cyclooxygenase-2 and thromboxane synthase are overexpressed in bone metastasis of breast and prostate carcinomas. Mod Pathol 17:141A, 2004.

269. Butler C, Altinok G, Andea A, Kolizeras K, Jenkins C, Che M, Grignon D, Sakr W. Topography of early prostatic neoplasia: Clinical and carcinogenesis implications for an outer peripheral “subcapsular” location, a morphologic and tissue micro array immunohistochemical study. Mod Pathol 17:144A, 2004.

270. Grignon DJ, Bismar TA, Bianco F, Sakr WA, Pontes JE, Sarkar F, Che M. VHL gene mutations in multilocular cystic renal cell carcinoma: Evidence in support of its classification as a type of clear cell renal cell carcinoma. Mod Pathol 17:154A, 2004.

271. Grignon DJ, Bismar TA, Bianco F, Sakr WA, Pontes JE, Che M. Pathologic findings in partial nephrectomy specimens and their clinical significance. Mod Pathol 17:154A, 2004.

272. Sakr W, Kolizeras K, Andea A, Powell I, Pontes JE, Che M, Grignon D. Prognostic parameters of needle biopsy (Bx) and radical prostatectomy specimens (RPS) relevant to age of diagnosis: Pathological analysis of 2895 African American (AA) and 2016 Caucasian men. Mod Pathol 17:175A, 2004.

273. Shen R, Zhang H, Bentley G, Ali R, Bianco F, Sakr W, Grignon D, Che M. Pathological stages of radical cystectomy: Comparison of clinicopathological features and molecular marker profiles of lower and higher stage tumors. Mod Pathol 17:177A, 2004.

274. Zhang H, Shen R, Ali-Fehmi R, Bianco F, Butler C, Sakr W, Grignon D, Che M. Characteristic immunohistochemical profiles and aggressive behavior of micropapillary and other histological variants and subtypes of urothelial carcinoma. Mod Pathol 17:187A, 2004.

275. Zhang H, Nie D, Li X, Sakr W, Grignon D, Che M, Honn KV. Role of thromboxane synthase expression in prostate cancer progression. Mod Pathol 17:187A.

Invited Lectures/Presentations/Chairs

1. "Prostatic Neoplasms" Continuing Medical Education Program, The University of Western Ontario, London, Canada, May, 1986.

2. "Current Concepts in Prostatic Pathology" Continuing Medical Education Program, The University of Western Ontario, London, Canada, March 31, 1989.

3. "Recent Advances in Prostate Cancer: A Pathologist's Perspective." National Defense Medical Center, Ottawa, Canada, February 2, 1990.

4. "Clinicopathologic Aspects of Prostatic Intraepithelial Neoplasia and Stage A Carcinoma of the Prostate." Hamilton Regional Cancer Centre, Hamilton, Ontario, October 18, 1990.

5. "DNA Flow Cytometry." St. Joseph's Institute of Laboratory Medicine Symposium, London, Canada, April 25, 1991.

6. Panelist, Specialty Conference - Genitourinary Pathology. "Adenocarcinoma Arising in Villous Adenoma of the Urachus." United States and Canadian Academy of Pathology, Atlanta, GA, March 18, 1992.

7. "DNA Studies in Early Stage Prostate Cancer." Coulter Electronics Speaker, Canadian Congress of Laboratory Medicine, Toronto, Ontario, June 24, 1992.

8. Chairman, Proferred Paper Session, "Genitourinary Pathology," United States and Canadian Academy of Pathology, New Orleans, LA, March 16, 1993.

9. "Recent Advances in Prostate Cancer: From Surgical Pathology to Molecular Genetics." Visiting Professor, The University of Western Ontario Laboratory Medicine Residents' Research Day. London, Ontario, Canada. April 16, 1993.

10. "Pathology of Benign Prostatic Hyperplasia." International Symposium on BPH and Prostate Cancer, Dearborn, MI. May 12, 1993.

11. "BPH, Is it a Premalignant Condition?" 1st International Conference on the Epidemiology of Early Prostate Cancer, Wayne State University, Detroit, MI, November 17, 1993.

61. Invited Faculty Member, UCSF/Stanford Surgical Pathology Course, San Francisco, CA, May 21-23, 1998.

62. "Prognostic Markers in Prostate Cancer: Do We Need More Than PSA and Gleason Score?"

Windsor Area Urology Group, Windsor, Canada. May 28, 1998.

63. Prognostic Markers in Prostate Cancer: A Practical Approach. International Academy of Pathology meeting, Nice, France, October 19,1998.

64. Pathology of Prostate Cancer. Future Trends in Prostate Cancer, Hamilton Regional Cancer Center, Hamilton, Canada. November 17, 1998.

65. Gleason Grading of Prostate Cancer: Problems and Pitfalls, Prognostic Markers in Prostate Cancer and Therapeutic Effects of Radiation Therapy and Chemotherapy on Prostate Cancer. Day in Prostate Pathology, Hamilton, Canada, November 18, 1998.

66. Conference organizer and chairman, 4th International Conference on Neoadjuvant Hormonal Therapy in Prostate Cancer - Special Pathology Meeting, Chicago, IL, January 29, 1999.

67. Handling and reporting of specimens from patients treated with neoadjuvant hormonal therapy, 4^th International Conference on NHT, Boston, MA, March 14, 1999.

68. Pathologic prognostic indicators in prostate cancer at the time of diagnosis. College of American Pathologists Meeting, Orlando, FL, April 12, 1999.

69. Co-chair, Prostate Cancer Committee, College of American Pathologists Conference XXXV, Prognostic markers in solid tumors, Chicago, IL, June 11-12, 1999.

70. “New Diagnostic Terminology for Urothelial Tumors.” ASCP Meeting, Boston, MA, April 10, 2000.

71. “Gleason grading of prostate cancer after neoadjuvant hormonal therapy.” Fourth International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer, Boston, MA, March 18, 2000.

72. “Pathology of Bladder Cancer.” Jaffar Oncology Conference, Providence Hospital, Dearborn, MI, September 15, 2000.

73. “Prognostic Markers in Prostate Cancer” and “Classification of Kidney Tumors.” Southwestern Ontario Urology Meeting, Niagara-on-the-Lake, Canada, September 30, 2000.

74. Selected topics in prostate pathology, biopsy diagnosis in surgical pathology. Kona, Hawaii, October 16-18, 2000.

75. “Classification of Urothelial Neoplasms” and “Benign Mimics of Bladder Neoplasms.” California Society of Pathologists, San Francisco, CA, November 30, 2000.

76. “What’s new in the pathology of urothelial carcinoma.” Case Western Reserve University, Cleveland, OH, March 9, 2001.

77. “Pathologic prognostic markers in renal cell carcinoma.” Baylor College of Medicine, Houston, TX, April 27, 2001.

78. “Prognostic parameters and histologic variants of urothelial carcinoma.” Houston Society of Clinical Pathologists, Houston, TX, April 28, 2001.

79. “Prognostic markers and the prostate needle biopsy.” Emory University, Atlanta, GA, October 15, 2001.

80. “Prognostic markers in renal cell carcinoma” and “The 1998 WHO/ISUP classification of urothelial tumors.” Turkish Pathology Society, Adana, Turkey, October 22, 2001.

81. “Grading of renal cell carcinoma: The good, the bad and the ugly.” United States/ Canadian Academy of Pathology, Chicago, IL, February 23, 2002.

82. “Cystic tumors and tumor-like lesions of the kidney,” “Prognostic parameters in the prostate needle biopsy” and “Non transitional neoplasms of the urinary bladder,” Second Annual Banff Surgical Pathology Course, The University of Calgary, Banff, Alberta, Canada, September 6-8, 2002.

83. “Update on the classification of renal cell carcinoma,” Pacific Northwest Pathology Society, Portland, Oregon, September 20-22, 2002.

84. “Pathologic prognostic parameters in the prostate needle biopsy” and “Clinical significance of the current classification of renal cell carcinoma,” Northeastern section, American Urological Association meeting, Mt. Tremblant, Quebec, Canada, September 27-29, 2002.

85. “Pathologic prognostic parameters in the prostate needle biopsy” and “Clinical significance of the current classification of renal cell carcinoma,” University of Western Ontario, Urologic Oncology Update, Gravenhurst, Ontario, Canada, October 4-6, 2002.

86. “Bladder cancer grading,” “Reporting of bladder cancer specimens,” “Diagnostic criteria for prostatic adenocarcinoma and small acinar proliferations,” “Prognostic parameters in prostatic adenocarcinoma,” and “Prognostic parameters in renal cell carcinoma,” Review Course in Urologic Pathology, Tatta Memorial Hospital, Mumbai, India, January 9-11, 2003.

87. “Pathologic features of signficance to basic science studies of prostate cancer,” 3^rd Annual Michigan Prostate Cancer Colloquium, Detroit, MI, March 29, 2003.

88. “Unusual subtypes of prostate cancer,” Long Course, United States/Canadian Academy of Pathology, Washington, DC, March 26, 2003.

89. “Histologic variants of urothelial carcinoma,” American Society of Clinical Pathology, New Orleans, LA, September 19, 2003.

90. “Diagnostic criteria for minimal cancer in prostate needle biopsies” and “2003 WHO classification of urothelial neoplasms,” University of Toronto Surgical Pathology Conference, Toronto, Canada, November 7, 2003.

91. Multiple lectures on selected topics in kidney, urinary bladder, prostate, and testicular pathology, University of Sao Paulo, Sao Paulo, Brazil, November 19-22, 2003.

92. “Mucinous tubular and spindle cell carcinoma of kidney,” USCAP Surgical Pathology evening session, Vancouver, Canada, March 8, 2004.

93. “Minimal diagnostic criteria for prostatic adenocarcinoma in needle biopsy.” University of Kentucky, Lexington, April 15, 2004.

94. “Selected problems in urinary bladder pathology” and “Unknown case discussions,” South Bay Pathology Society Annual Meeting, Monterey, CA, May 1, 2004.

95. “Current classification of renal epithelial neoplasms with emphasis on differential diagnosis and new entities” and “Small acinar lesions of the prostate gland and minimal diagnostic criteria for adenocarcinoma,” University of Texas-Southwestern, Dallas, TX, May 14, 2004.

96. “Gleason grading of prostate cancer: A contemporary approach,” and “2004 WHO classification of kidney tumors,” Ohio State University, September 12, 2004.

97. “Current classification of urothelial neoplasms” and “Clinical relevance of the current classification of renal cell carcinoma,” Upstate University Medical Center, Syracuse, NY, September 29-30, 2004.

98. “Prostatic intraepithelial neoplasia, current concepts” and “Ductal adenocarcinoma of the prostate,” International Academy of Pathology, Brisbane, Australia, October 15, 2004.

Slide Seminars and Short Courses

1. Slide seminar: "Neoplasms of the Testis." The University of Ottawa, Ottawa, Canada, February 2, 1990.

2. Slide seminar: "Histologic Grading of Prostatic Adenocarcinoma." McMaster University, Hamilton, Ontario, October 18, 1990.

3. Short course: "Surgical Pathology of the Urothelial Tract" (given with Dr. J. R. Srigley, Sunnybrook Medical Centre, Toronto); Canadian Congress of Laboratory Medicine, St. John's, Newfoundland, June, 1990.

4. Short course: "Surgical Pathology of the Urothelial Tract" (given with Dr. J. R. Srigley, Sunnybrook Medical Centre, Toronto); Canadian Congress of Laboratory Medicine and World Association of Societies of Pathology, Vancouver, BC, June, 1991.

5. Short course: "Surgical Pathology of the Urothelial Tract" (given with Dr. J. R. Srigley, Sunnybrook Medical Centre, Toronto); Canadian Congress of Laboratory Medicine, Toronto Ontario, June 1992.

32. Short Course, "Controversies in Urologic Pathology," Dr. L. True, U of Washington, Course Co-director, American Society of Clinical Pathologists Weekend in Pathology, Las Vegas, NV, February 14, 1997.

33. Faculty, American Urological Association Board Review Course, Dallas TX, February 15-17, 1997.

34. Short Course, "Surgical Pathology of the Urothelial Tract" United States Canadian Academy of Pathology Meeting, Orlando, FL, March 6, 1997.

35. Short Course "Surgical Pathology of Prostate Cancer: Its Precursors and Mimics" (given with Dr. W.A. Sakr), USCAP Meeting, Orlando, FL, March 7, 1997.

36. Workshop, "Tumors and Tumor-like Lesions of the Kidney and Ureter" (given with Dr. J. Eble, Indiana University), American Society of Clinical Pathologists Meeting, Chicago, IL, April 6, 1997.

37. Workshop, "Tumors and Tumor-like Lesions of the Kidney and Ureter" (given with Dr. J. Eble, Indiana University), American Society of Clinical Pathologists Meeting, Los Angeles, CA, April 5, 1998.

38. Short Course, "Controversies in Urologic Pathology," Dr. L. True, U of Washington, Course Co-director, American Society of Clinical Pathologists Meeting, Los Angeles, CA, April 6, 1998.

39. Slide Seminar (Chairman), “Genitourinary Pathology” International Academy of Pathology Meeting, Nice, France, October 19, 1998.

40. “Non-transitional Neoplasms of the Bladder” and “Pathology of Kidney Tumors” at American Society of Clinical Pathologists course in Genitourinary Pathology, Williamsburgh, VA, December 11-12, 1998.

41. Faculty, American Urologic Association Pathology Board Review Course, Dallas, TX, February 13-15, 1999.

42. Organized and presented (with Dr. Wael Sakr and Dr. Edson Pontes), 5-day course in Urologic Oncologic Pathology, University of Sao Paulo, Sao Paulo, Brazil, July 26-30, 1999.

43. Short Course, ASCP Fall Meeting, Current Concepts in Kidney and Bladder Pathology, New Orleans, LA, October 12, 1999.

44. Faculty, American Society of Clinical Pathologists Special Course in Urologic Pathology, Scottsdale, AZ, November 17-19, 1999.

45. Faculty, American Urological Association Board Review Course, Dallas, TX, February 12-14, 2000.

46. Faculty, USCAP Diagnostic Pathology 2000, Atlanta, GA, August 7, 2000.

47. Faculty, American Society of Clinical Pathology, Special Course in Urologic Pathology, St. Petersberg, FL, November 2000.

48. Faculty, American Urological Association Board Review Course, Dallas, TX, February 9-12, 2001.

49. Workshop, "Tumors and Tumor-like Lesions of the Kidney and Ureter" (given with Dr. J. Eble, Indiana University), American Society of Clinical Pathologists Meeting, Las Vegas, NV, February 24, 2001.

50. Faculty, USCAP Diagnostic Pathology 2001, Monterey, CA, August 3, 2001.

51. Slide seminar. Tumors of the Kidney, Turkish Society of Pathology, Adana, Turkey, October 22, 2001.

52. Faculty, American Society of Clinical Pathology, special course in urologic pathology, Dana Point, CA, November 15-16, 2001.

53. Short Course, “Current Controversies in Kidney, Urinary Bladder and Prostate Pathology.” American Society of Clinical Pathology, Santa Monica, CA, June 7, 2002.

54. Faculty, American Urological Association Genitourinary Pathology Program, Dallas, TX, June 19-21, 2002.

55. Diagnostic Pathology Review Course, “Grading of papillary urothelial neoplasms and variants of TCC” and “Minimal diagnostic criteria for prostatic adenocarcinoma and practical approach to Gleason Grading.” United States/Canadian Academy of Pathology, Bar Harbor, ME, July 19, 2002.

56. Slide seminar, “Controversial cases in urologic pathology,” Second Annual Banff Surgical Pathology Course, Banff, Alberta, Canada, September 6-8, 2002.

57. Slide seminar, “Challenging lesions of the kidney, urinary bladder and prostate gland,” Pacific Northwest Pathology Society Annual meeting, Portland, Oregon, September 20-22, 2002.

58. Faculty, American Society of Clinical Pathology, special course in urologic pathology, Toronto, Canada, October 3-4, 2002.

59. Interactive slide seminar on “Pathology of the prostate gland” (given with Dr. Wael Sakr), International Academy of Pathology, Amsterdam, Netherlands, October 10, 2002.

60. Faculty, USCAP Diagnostic Pathology 2003, Bar Harbor, ME, July 17-18, 2003.

61. Faculty, AUA Pathology Board Review Course, Chicago, IL, August 6-8. 2003.

62. Slide seminar, “Challenging cases in Urologic Pathology,” University of Toronto Surgical Pathology Conference, Toronto, Canada, November 17, 2003.

63. Multiple slide seminars on topics in kidney, urinary bladder, prostate, and testicular pathology, University of Sao Paulo, Sao Paulo, Brazil, November 19-22, 2003.

64. Faculty, American Society of Clinical Pathology, special course in urologic pathology, Colorado Springs, CO, December 11-12, 2003.

65. Slide seminar: “Challenging lesions in kidney tumor pathology,” University of Kentucky, Lexington, April 16, 2004.

66. Faculty, United States/Canadian Academy of Pathology Diagnostic Pathology Course, Banff, Canada, July 29, 2004.

67. Faculty, American Urological Association Board Review Course, Chicago, IL, July 31-August 3, 2004.

68. “Advances in the surgical pathology of bladder cancer,” International Academy of Pathology, Brisbane, Australia, October 14, 2004.

69. Faculty, American Society of Clinical Pathology, special course in urologic pathology, Banff, Canada, October 28-29, 2004.

Grants

1. DNA flow cytometry of prostatic adenocarcinoma. Victoria Hospital Research and Development Fund. ($8,726.76); 01/89 - 12/89. (Co-investigators: J. Wyatt MD and R. Lohman MD).

a) Apoptosis related genes in prostate cancer

b) Principal Investigator (15% effort)

c) 9/1/96 - 8/31/98

d) $100,000 (contract) (9/1/96 - 8/31/97)

10. U. S. Army Medical Research Prostate Cancer Research Program

a) Bioactive Lipids: Role in Prostate Cancer Angiogenesis

b) Coinvestigator (5% effort); K. Honn, PhD, PI

c) 1998

d) $468,750.00

11. WSU Prostate Cancer Initiative

a) Maspin in Prostate Cancer

b) Coinvestigator (5% effort); S. Sheng, PhD, PI

c) 1998-1999

d) $80,000.00

12. NIH N02-CP-11004

a) Study Centers for Case Control Study of Renal Cell Cancer Among Caucasians and African Americans

b) Coinvestigator (10% effort); K. Schwartz, PI

c) 2001-2005

Other Academic Activities

1. Laboratory Instructor, General and Systemic Pathology Course, First and Second year Medicine, Wayne State University, Detroit, MI, 1992 - present.

2. Lecturer, Cancer and Radiation Biology Course, Biological Sciences 565, Wayne State University, Detroit, MI, 1993 - present.

3. Supervision and teaching of AP/CP Residents, Department of Pathology, Wayne State University, Detroit, MI, 1992 - present.

4. Coordinator and lecturer, didactic pathology seminar series, Department of Urology, Wayne State University, Detroit, MI, 1992 - present.

5. Lecturer, Systemic Pathology course, 2nd year medicine: covering diseases of the Kidney, Upper Urinary Tract, Urinary Bladder, Prostate Gland, Testes, and External Male Genitalia, The University of Western Ontario, London, 1988-1992.

6. Supervision and teaching of residents in Anatomic and General Pathology; day to day supervision, slide seminars, and didactic lectures, The University of Western Ontario, London, 1988-1992.

7. Supervisor, Urological Surgery Residents during elective rotations in Genitourinary Pathology (3 month electives in the Pathology Department, 2 residents per year), The University of Western Ontario, London, 1989-1992.

8. Lectures to Urological Surgery Residents and Radiation Oncology Residents on Genitourinary Pathology as part of their didactic teaching sessions, The University of Western Ontario, London, 1988-1992.

9. Faculty Adviser, M.Sc. Thesis, Dr. Tom Mara, Department of Oral Pathology, The University of Western Ontario. "AgNOR staining and normal, reactive, dysplastic and neoplastic squamous mucosa of the oral cavity." July 1989 - present.

10. Examiner, Ph.D. Thesis, Dr. M. Zanyk. "An immunobiological study of natural killer cells." The University of Western Ontario, Department of Pathology, July, 1990.

11. Invited participant, Terry Fox Workshop on The Molecular Biology of Soft Tissue Sarcomas, London, Ontario, December 10 and 11, 1990.

Prizes and Awards

Ontario Association of Pathologists' Award for best paper by a resident, OAP Annual Meeting, Hamilton, Ontario, September 21, 1984. "Changes in immunohistochemical staining of prostatic adenocarcinoma after diethylstilbestrol therapy." (Dr. M. Troster, Supervisor)

Award for best paper, Residents' Research Day, The University of Western Ontario, London, Ontario, May 23, 1985. "Changes in immunohistochemical staining of prostatic adenocarcinoma after diethylstilbestrol therapy." (Dr. M. Troster, Supervisor)

Don Penner Award for best paper given by a resident, Canadian Congress of Laboratory Medicine, Edmonton, Alberta, June 25, 1985. "Cross reactivity of a monoclonal pan-T cell antibody (anti-Leu 4) with prostatic epithelium." (Dr. D. Banerjee, Supervisor)

Editorial Board Memberships

Administrative Experience

Books

Other

Slide Seminars and Short Courses

Grants

Other Academic Activities

Personal Data